Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 1102 Nifty 500 stocks· EOD 2026-06-18

Camlin Fine Sciences Limited

CAMLINFINE · NSE · Basic Materials

₹137.19
-2.90 (-2.07%)
Buy zoneStrong Sell
The bottom line

StocksWizard rates Camlin Fine Sciences Limited a Strong Sell, scoring 26/100 on our blended model. At ₹137.19 it trades above our blended DCF and relative-multiples fair value of ₹99.13, implying roughly 28% downside to that estimate — we read the stock as overvalued by 28%. Financial health scores 28/100 (grade F), in the grey band on the Altman Z-score, with a Piotroski F-score of 5/9. It clears 2 of 12 investability checks, with durability 17, valuation 66 and momentum 33 on our 0–100 scales.

These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Our verdictSolvency risk
Strong Sell26/100
Quality17
Valuation35
Momentum33
Financial trend18
Intrinsic value
Our fair value
₹99.13
Overvalued by 28%
Price ₹137.19Range ₹68.6₹173.55

With a 20% margin of safety, our buy-below price is ₹79.3.

F
Financial health 28/100
Altman Z 2.13 · Grey zone

Piotroski F-score 5/9 — quality of earnings & balance sheet.

Investability checklist

Passed 2 of 12 checks17/100
  • ROE above 15%-3.4%
  • Low debt (D/E < 0.5)0.72x
  • Positive free cash flow
  • Revenue growth > 10%-3%
  • Earnings growing
  • Net margin ≥ 10%1.6%
  • Current ratio > 1.51.27
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 2.13
  • Piotroski ≥ 75/9

1-year price

EOD · 2026-06-18
1W
+10.0%
1M
+13.2%
3M
+6.6%
6M
-16.3%
1Y

Our scores

Durability17
Valuation66
Momentum33

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Quarterly results

2Q2025₹424 Cr revenue
Net profit ₹-10 Cr-2% margin
3Q2025₹460 Cr revenue
Net profit ₹-5 Cr-1% margin
4Q2025₹457 Cr revenue
Net profit ₹-19 Cr-4% margin
1Q2026₹425 Cr revenue
Net profit ₹15 Cr3% margin
Revenue Net profitLatest revenue QoQ -7%

Annual financials

2022₹1,412 Cr revenue
Net profit ₹61 Cr4% margin
2023₹1,682 Cr revenue
Net profit ₹57 Cr3% margin
2024₹1,613 Cr revenue
Net profit ₹-43 Cr-3% margin
2026₹1,723 Cr revenue
Net profit ₹-5 Cr-0% margin
Revenue Net profitLatest revenue YoY +7%

Shareholding

Promoter44.1%
Institutions17.2%
Public & other38.7%

Promoter holding via insider stake; institutional via reported holdings.

Analyst views

2 analysts1 buy · 1 hold · 0 sell
12-month consensus target₹177.5+29%
Low ₹165High ₹190

Key fundamentals

Market cap
₹2,635 Cr
P/E ratio
16.8
P/B ratio
2.53
EPS (TTM)
₹-1.59
ROE
-3.4%
Debt / Equity
0.72x
Profit margin
1.6%
Free cash flow
₹91 Cr
52-week high
₹327.53
-58.11% from high
52-week low
₹96.93
Dividend yield
Beta
0.65

SWOT snapshot

Weaknesses

  • Low return on equity (-3.4%).
  • Price below its 200-day moving average (downtrend).

Opportunities

  • Trading in our value buy zone versus sector peers.
  • Well off its 52-week high — possible mean-reversion.

Threats

  • Trades ~28% above our estimated fair value.

About Camlin Fine Sciences Limited

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanilli

More in Basic Materials

All stocks

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.